Siemens Healthcare has introduced Biograph mCT Flow, a positron emission tomography/computed tomography (PET/CT) system that, for the first time ever, overcomes the limitations of conventional bed-based PET/CT with FlowMotion, a revolutionary new technology that moves the patient smoothly through the system’s gantry, while continuously acquiring PET data. Biograph mCT Flow with FlowMotion takes routine image quality to a new level by enabling imaging protocols based on the organ’s need.

The phrase “doing more with less” is becoming more prevalent in tightening economic environments, and the operating room (OR) is one example of where hospitals are looking to maximize savings. Mobile C-arm units are important for maximizing space in the OR and can provide the image quality needed to visualize anatomy and devices during complex surgical procedures. The latest advances in mobile C-arms aim to provide users with the flexibility and ergonomics that can support accomplishing more in the OR with less.

New long-term data from the DIVERGE study, presented at EuroPCR 2013 by Principal Investigator Dr. Stefan Verheye, Antwerp Cardiovascular Centre, ZNA Middelheim Hospital, Belgium, has shown that the use of the Axxess drug-eluting stent (DES) for the treatment of complex coronary bifurcation lesions resulted in low levels of both MACE and VLST over a five-year period. Axxess is now the only dedicated bifurcation stent with a substantial body of supporting data out to five years.

Between June and October, 2013, healthcare providers at hospitals and medical centers across the United States and Canada can experience GE Healthcare’s entire line of Centricity* Imaging technologies when the Centricity Imaging IT Tour visits locations in over 30 major markets.

eHealth Technologies’ eHealthViewer ZF is a zero footprint viewer that enables clinicians, with any secure browser, to instantly access their patients’ medical images, in diagnostic-quality, right from within their patients’ medical record. The latest enhancement to the eHealthViewer ZF is Image Collaboration.  Whether through consultation with a remote specialist or grand rounds with the patients’ clinical care team, the eHealthViewer ZF collaboration tool delivers real-time, fluid image review and interaction for healthcare professionals. Using this singular feature, multiple users at different locations, can interactively view and manipulate radiology and cardiology images with full access to the eHealthViewer ZF advanced toolset.

Just a few years ago, integrated positron emission tomography and magnetic resonance (PET/MR) imaging was found only in research institutes, but little by little the technology has expanded into clinical practice. This is especially true for cardiac indications, for which the highly sensitive soft tissue contrast of MR and the functional and metabolic imaging of PET are particularly valuable. New research proves the value of PET/MR compared to PET/computed tomography (CT) in cardiac applications, say researchers at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting.

Direct Flow Medical Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the SALUS feasibility trial of the Direct Flow Medical Transcatheter Aortic Heart Valve System. The device encompasses a transcatheter aortic heart valve with a metal-free frame and flexible, low-profile delivery system that virtually eliminates aortic regurgitation. It is designed to improve the long term survivability of patients by resolving the clinical issues associated with current commercial valves.

C. R. Bard Inc. announced the enrollment of the first patient into the Lutonix Below the Knee (BTK) Clinical Trial at The Cardiac and Vascular Institute in Gainesville, Fla. The purpose of this pivotal global, multi-center randomized Investigational Device Exemption (IDE) trial is to compare the safety and effectiveness of the Lutonix 014 Drug Coated PTA Dilatation Catheter to a standard angioplasty balloon catheter for the treatment of critical limb ischemia.

AngioLight has successfully completed an initial animal study of the AngioLight System at Fu Wai Hospital, a leading cardiovascular center located in Beijing. The study paves the way for AngioLight to go forward in China with full-scale animal and clinical testing of the system, which will begin following the anticipated completion of study protocols, hospital review and required China Food and Drug Administration (CFDA) approvals.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now